Which patients are SaPHe in sarcoidosis-associated pulmonary hypertension?
- PMID: 32409427
- DOI: 10.1183/13993003.00700-2020
Which patients are SaPHe in sarcoidosis-associated pulmonary hypertension?
Conflict of interest statement
Conflict of interest: D. Vis has nothing to disclose. Conflict of interest: A. Boucly reports personal fees and non-financial support from Actelion, personal fees from MSD, outside the submitted work. Conflict of interest: M. Humbert reports personal fees from Acceleron, Merck, Morphogen IX and United Therapeutics, grants and personal fees from Actelion, Bayer and GSK, outside the submitted work. Conflict of interest: J. Weatherald reports grants, personal fees and non-financial support from Janssen Inc. and Actelion, personal fees and non-financial support from Bayer, personal fees from Novartis, grants from Alberta Lung Association, Canadian Vascular Network, European Respiratory Society and Canadian Thoracic Society, outside the submitted work.
Comment on
-
Physiological predictors of survival in patients with sarcoidosis-associated pulmonary hypertension: results from an international registry.Eur Respir J. 2020 May 14;55(5):1901747. doi: 10.1183/13993003.01747-2019. Print 2020 May. Eur Respir J. 2020. PMID: 32139456
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical